This OHE Research Paper describes a study in which four stated preference methods for anchoring EQ-5D-Y values were compared: visual analogue scale, discrete choice experiment (with a duration attribute), lag-time time trade-off, and the recently developed ‘location-of-dead’ element of the personal utility function (PUF) approach.
OHE has been awarded a 3-year research grant by the Health Foundation’s Efficiency Research Programme to define an accurate measure of labour productivity in primary care and to identify its determinants, including workforce skill mix, technology and patient characteristics.
Chronic diseases affect individuals’ health status and its impact is reflected by the stock of health, which measures the amount of health of a population in a given period of time. In a new study published in Health Economics, Maria Errea and colleagues assess the health-related quality of life of a population using the EQ-5D-5L instrument to, first, estimate the impact of a set of 30 chronic diseases and, second, rank diseases according to their impact on the stock of health for a country.
Research by OHE and the University of Sussex into patients’ preferences for diagnostic tests aimed at reducing antimicrobial resistance has been published in Applied Health Economics & Health Policy. The research found that patients across Europe have different preferences, which may have significant implications for the design and uptake of diagnostic tests.
OHE, in collaboration with RAND Europe, University College London (UCL) and University of Manchester (UoM), has been awarded a new research grant from Cancer Research UK in partnership with Greater Manchester Health & Social Care Partnership (GMHSCP) to further explore the potential of implementing outcome-based payments for cancer treatments.
New research published in Economics and Human Biology demonstrates that elevated blood tests and nurse-collected physical measures predict progression to disability two to four years ahead for individuals without a disability history.
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long-run.